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Background: This study investigated adjuvant chemotherapy (AC) 
use after esophagectomy without induction therapy for node-positive 
(pN+) adenocarcinoma using the National Cancer Database, including 
the impact of complications related to surgery (CRS) on outcomes.
Methods: Predictors of AC use in 1694 patients in the National Cancer 
Data Base who underwent R0 esophagectomy from 2003–2011 with-
out induction therapy for pN+ adenocarcinoma of the middle or lower 
esophagus and survived more than 30 days were identified with mul-
tivariable logistic regression. The impact of AC on survival was esti-
mated using Kaplan–Meier and Cox-proportional hazards methods.
Results: AC was given to 874 of 1694 (51.6%) patients; 618 (70.7%) 
AC patients received radiation. Older age (adjusted odds ratio 
[AOR] 0.58/decade, p < 0.001), longer travel distance (AOR 0.78 
per 100 miles, p = 0.03) and CRS (AOR 0.45, p < 0.001) predicted 
that AC was not used. Patients given AC had better 5-year survival 
than patients not given AC (24.2% versus 14.9%, p < 0.001), and 
AC use predicted improved survival in multivariate analysis (hazard 
ratio 0.67, p = 0.008). Receiving radiation in addition to AC did not 
improve survival (p = 0.35). Although CRS was associated with worse 
survival, patients who had CRS but received AC had superior survival 
compared to patients who did not have CRS or get AC (p = 0.016).
Conclusions: AC after esophagectomy is associated with improved 
survival but was only used in half of patients with pN+ esophageal 
adenocarcinoma. We also found that the addition of radiation to AC 
was not associated with a survival benefit. CRS predict worse long-
term survival and lower the chance of getting AC, but even patients 
with CRS had improved survival when given AC.
Key Words: Esophageal cancer, Adjuvant chemotherapy, 
Postoperative complications.
(J Thorac Oncol. 2015;10: 181–188)
Approximately 57% of all esophageal cancers in the United States are adenocarcinomas, with an increasing incidence 
in recent years.1–6 Esophageal adenocarcinomas are found in the 
distal esophagus in three quarters of cases.2 Overall approxi-
mately 32% of esophageal cancer patients have regional disease 
at the time of diagnosis.1,2,7 The treatment for locally advanced 
esophageal cancer that does not have distant metastases and is 
potentially resectable (T3-4aN0, T1-4aN1M0) is highly variable 
in practice.8 However, recent evidence suggests that induction 
chemoradiation followed by surgical resection is the optimal 
treatment for patients with nodal disease (pN+).9–15 For patients 
with pN+ adenocarcinoma who are treated primarily with sur-
gical resection, the National Comprehensive Cancer Network 
guidelines recommend adjuvant chemoradiation.16
However, the use of adjuvant therapy after esophagec-
tomy for adenocarcinoma has not been well characterized. 
Recommendations related to adjuvant therapy for esophageal 
adenocarcinoma are derived from trials that exclusively or pre-
dominantly included patients with gastric carcinoma.17–23 One 
potential difficulty with translating results from those studies 
is that a patient’s ability to tolerate adjuvant treatment may dif-
fer between gastrectomy and esophagectomy. Esophagectomy 
is associated with significant morbidity despite improvements 
over time, and complications can more than double already long 
hospital stays and overall recovery periods.24–31 Both patients 
and their providers may be reluctant to consider potential 
risks associated with adjuvant therapy after esophagectomy, 
especially if the patient had a difficult perioperative course. 
Currently the paucity of data regarding the use of adjuvant ther-
apy limits clinicians’ ability to appropriately counsel patients on 
the risks and benefits. This study was undertaken to examine the 
role of adjuvant therapy after surgical resection for adenocarci-
noma of the esophagus using a large national clinical database 
and attempt to improve the available level of evidence, particu-
larly with regard to the potential benefits of adjuvant oncologic 
therapy in patients with postoperative complications.
METHODS
This retrospective analysis of patients in the National 
Cancer Data Base (NCDB) undergoing esophagectomy for 
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esophageal cancer from 2003–2011 was approved by the Duke 
University Institutional Review Board. The NCDB currently 
contains over 30 million records by collecting data from more 
than 1500 CoC-approved facilities across the United States, and 
is estimated to capture approximately 70% of all newly diag-
nosed U.S. cases of cancer annually. Patients with adenocarci-
noma of the mid- and distal third of the esophagus were identified 
using International Classification of Diseases for Oncology, 3rd 
Edition topography and histology codes. Pathologic (tumor, 
node, metastasis) TNM staging data was directly extracted 
using the American Joint Commission on Cancer 6th and 7th 
edition staging manuals depending on year of diagnosis, and 
only patients with N+ disease were kept for analysis. As our pri-
mary predictor variable was the use of adjuvant chemotherapy 
(AC) after oncologic resection, only patients with negative (R0) 
margins who survived at least 30 days postoperatively were 
included. Patients who received induction therapy of any kind 
were excluded, as were patients with missing data regarding the 
specific timing of chemoradiation therapies.
Patients were stratified into two groups based on the 
use of AC versus postoperative observation. Baseline patient 
characteristics and postoperative outcomes were compared 
using the Mann-Whitney U test for continuous variables and 
Pearson’s chi-square test for discrete variables. Trends over 
time were examined with the Cochran-Armitage trend test. 
Because the NCDB does not contain data regarding specific 
perioperative morbidity, we defined postoperative complica-
tions as cases that involved either an unplanned readmission, 
or a length of stay of at least 20 days after esophagectomy. 
Predictors of AC were identified using multivariable logistic 
regression modeling, which included age, sex, race, Charlson/
Deyo comorbidity score, median census tract education and 
income levels, TNM pathologic T stage, patient distance from 
treatment facility, and presence of a postoperative complica-
tion as defined above.
The Kaplan–Meier method was used to estimate overall 
survival, which was defined as time from diagnosis to death or 
censor. Cancer-specific survival is not available in the NCDB. 
To estimate the independent effect of AC on survival, a Cox 
proportional hazards model was developed that included age, 
sex, race, comorbidity burden, pathologic T stage, and treat-
ment facility volume. To examine whether postoperative com-
plications were confounding any potential differences between 
the treatment groups, we conducted a subgroup analysis of 
assessing long-term survival only for those patients who did 
not experience a complicated course. Likewise, we explored 
survival among patients who received AC, stratified by the 
presence of postoperative complications, focusing on how res-
cue from such complications affects survival for patients who 
received AC, compared to patients receiving AC in the setting 
of no major complications.
We made an affirmative decision to control for type 
I error at the level of each comparison. A p value less than 
0.05 was considered statistically significant for all compari-
sons. Missing data was handled with complete case analy-
sis given the substantial completeness of the NCDB for the 
study population investigated. All statistical analyses were 
performed using R version 3.0.2 (R Foundation for Statistical 
Computing, Vienna, Austria).
RESULTS
Of 1694 node-positive patients in the NCDB who did 
not receive induction therapy and survived at least 30 days 
after surgery, 874 (51.6%) were treated with AC, and 618 of 
these (70.7%) also received radiation therapy postoperatively. 
Use of chemotherapy significantly increased over time, from 
45% of patients in 2003 to 57% in 2011, p < 0.001 (Fig. 1). 
Baseline unadjusted characteristics are shown in Table 1, with 
the patients who received adjuvant therapy being younger, 
with lower comorbidity burden, were more likely to have pri-
vate insurance, and had significantly shorter hospital length 
of stays after esophagectomy. After multivariable adjustment, 
older age (adjusted odds ratio [AOR] 0.58/decade, p < 0.001), 
longer travel distance (AOR 0.78 per 100 miles, p = 0.03), 
and presence of postoperative complications (AOR 0.45, 
 p < 0.001) predicted that AC was not used (Table 2). A total of 
1470 (86.8%) patients had complete data regarding unplanned 
readmission and hospital length of stay. Of patients not 
FIGURE 1.  Trends in the use of adjuvant 
 chemotherapy after margin-negative, node-positive 
esophagectomy.
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experiencing postoperative complications, 587 (54.4%) were 
treated with AC, although among patients who experienced a 
complication, only 130 (33.3%) went on to received AC.
Median survival for patients given AC was 24.8 months 
versus 16.7 months for patients treated with surgery alone 
(p < 0.001, Fig. 2A). Patients given AC had better 5-year 
survival than patients not given AC (24.2% versus 14.9%), 
and AC use predicted improved survival in multivariable 
analysis (HR 0.67, p = 0.008, Table 3). Although postopera-
tive complications were associated with worse survival (HR 
1.5, p = 0.01), adjuvant therapy use was still associated with a 
significant survival advantage after excluding all patients who 
experienced a postoperative complication (5-year survival: 
24.7% versus 16.0%, p < 0.001; Fig. 2B). More importantly, 
patients who experienced postoperative complications and 
were subsequently rescued to receive intended AC had similar 
TABLE 1.  Baseline Characteristics Between Groups
Variable
Total  
(n = 1694)
No Chemotherapy 
(n = 820)
Adjuvant Chemotherapy 
(n = 874) p Value
Patient characteristics
Age, yr (IQR) 64 (56, 72) 67 (59, 75) 61 (54, 68) <0.001
Female 201 (11.9%) 106 (12.9%) 95 (10.9%) 0.217
Race 0.496
  White 1631 (97.2%) 790 (97.4%) 841 (97%)
  Black 25 (1.5%) 13 (1.6%) 12 (1.4%)
  Other 22 (1.3%) 8 (1%) 14 (1.6%)
Charlson comorbidity score <0.001
  0 1166 (68.8%) 532 (64.9%) 634 (72.5%)
  1 414 (24.4%) 211 (25.7%) 203 (23.2%)
  ≥2 114 (6.7%) 77 (9.4%) 37 (4.2%)
Education above median 1016 (63.1%) 492 (63.5%) 524 (62.7%) 0.777
Income above median 1100 (68.3%) 527 (68%) 573 (68.5%) 0.858
Insurance <0.001
  Private 811 (48.7%) 316 (39%) 495 (58%)
  Medicare 747 (44.9%) 439 (54.2%) 308 (36.1%)
  Medicaid 57 (3.4%) 30 (3.7%) 27 (3.2%)
  government 18 (1.1%) 8 (1%) 10 (1.2%)
  Uninsured 31 (1.9%) 17 (2.1%) 14 (1.6%)
Tumor characteristics
Tumor size (cm) 0.48
  <1 39 (2.5%) 19 (2.5%) 20 (2.5%)
  1–1.9 124 (8%) 65 (8.6%) 59 (7.4%)
  2–4.9 889 (57.3%) 440 (58.4%) 449 (56.3%)
  >4.9 499 (32.2%) 229 (30.4%) 270 (33.8%)
Pathologic T stage 0.872
  T1 307 (18.3%) 154 (18.9%) 153 (17.7%)
  T2 322 (19.2%) 159 (19.5%) 163 (18.8%)
  T3 999 (59.4%) 477 (58.5%) 522 (60.3%)
  T4 53 (3.2%) 25 (3.1%) 28 (3.2%)
Facility characteristics
  Distance to cancer center (IQR) 15.6 (6, 39.6) 20.2 (7.4, 54.4) 12.6 (4.8, 30.4) 0.016
Treatment facility <0.001
  Academic/Research Program 793 (47%) 438 (53.7%) 355 (40.8%)
  Community Program 893 (53%) 377 (46.3%) 516 (59.2%)
Surgical endpoints
  Nodes removed (IQR) 13 (8, 19) 13 (8, 19) 13 (9, 20) 0.334
Short-term outcomes
  30-day readmission 129 (8%) 74 (9.4%) 55 (6.7%) 0.064
  Hospital LOS (IQR) 11 (8, 16) 13 (9, 21) 10 (8, 14) <0.001
  Major complication 390 (26.5%) 260 (34.5%) 130 (18.1%) <0.001
IQR, interquartile range.
184 Copyright © 2014 by the International Association for the Study of Lung Cancer
Speicher et al. Journal of Thoracic Oncology ®  •  Volume 10, Number 1, January 2015
survival compared to patients who received AC in the absence 
of complications (p = 0.78, Fig. 3A), but had superior survival 
compared to patients who did not experience complications 
but also did not get AC (p = 0.016, Fig. 3B). In an explor-
atory analysis examining the effect of adding adjuvant radia-
tion therapy to AC, no significant improvement in survival 
was found between patients who were given AC and radiation 
compared to patients who were only given AC (p = 0.35).
DISCUSSION
In this study, we found that the use of AC after esopha-
gectomy is associated with significantly improved survival for 
patients for pN+ esophageal adenocarcinoma not treated with 
induction therapy. Despite increasing rates of AC use over time, 
we found that only approximately half of patients treated with 
esophagectomy without induction therapy for pN+ esophageal 
adenocarcinoma in the NCDB ultimately received AC treatment 
postoperatively. Although complications related to surgery both 
significantly lower the probability of treatment with AC and pre-
dict worse long-term survival overall, patients who adequately 
recover from complications and subsequently receive AC do 
derive benefits with respect to long-term survival.
The use of adjuvant therapy after esophagectomy for 
adenocarcinoma is poorly characterized. Recommendations 
related to adjuvant therapy for esophageal adenocarcinoma 
are derived from trials that exclusively or predominantly 
included patients with gastric carcinoma.17–23 The National 
Comprehensive Cancer Network recommendations for adju-
vant chemoradiation therapy after esophagectomy are primar-
ily based on the Intergroup-0116 study. In this study of 556 
patients with adenocarcinoma of the stomach or cardia, 85% 
of whom had pathologic nodal disease, patients given adju-
vant chemoradiation (45 gy combined with 5-FU and leu-
covorin) had significantly better 3 year survival compared to 
patients treated with surgery alone (50% versus 41%, HR 1.32, 
p = 0.0046).17,18 However, only 20% of these patients had can-
cer in the proximal stomach or gastroesophageal (gE) junc-
tion area. Similarly, the Adjuvant Chemoradiation Therapy in 
Stomach Cancer (ARTIST) trial compared adjuvant chemo-
radiation (two cycles cisplatin and capecitabine then 46 gy 
with capecitabine for 5 weeks and then two more cycles of cis-
platin and capecitabine) and chemotherapy alone (six cycles 
of cisplatin and capecitabine) in 458 patients with adenocar-
cinoma of the stomach or gE junction, and found chemora-
diation was associated with improved disease-free survival 
in the subgroup of patients who had pathologic lymph node 
metastases at the time of surgery, but overall no difference in 
3 year disease-free survival.19 Pathological nodal disease was 
present in 86% of the patients, but only 5% of patients had 
gE junction tumors. Similarly, studies of adjuvant chemother-
apy have also included very limited numbers of esophageal 
cancer patients. The Asian Phase III Adjuvant Chemotherapy 
Trial of S-1 for gastric Cancer was a study of 1059 Japanese 
patients with gastric adenocarcinoma, most of whom were 
stage II or III, that found adjuvant chemotherapy (1 year of 
the oral fluoropyrimidine S-1) was associated with better sur-
vival than surgery alone (71.7% versus 61.1%, HR 0.669).20,21 
However, this study only included patients with stomach 
cancer and involved a drug that is not widely used outside 
of Asia. The CLASSIC study did include patients with gE 
junction adenocarcinomas and found patients that were given 
adjuvant chemotherapy (eight cycles capecitabine and oxali-
platin) had better overall 5-year survival compared to patients 
treated with surgery alone (78% versus 69%, p = 0.0029).22,23 
This Asian trial of 1035 patients included 90% who had nodal 
disease, but 98% of included patients had gastric cancer with 
only the remaining 2% having gE junction cancers.
Using data related to gastric adenocarcinoma to guide 
treatment of esophageal adenocarcinoma does have some valid-
ity. Adenocarcinoma of the gE junction is treated and staged 
similarly to more proximal esophageal cancers of the proximal 
esophagus, but is considered to be significantly less radiosen-
sitive than other esophageal cancers and is biologically more 
closely related to gastric adenocarcinoma.32 However, surgi-
cal resection and subsequent reconstruction of gastrointes-
tinal continuity for esophageal cancer is more complex than 
that for gastric cancer, which can impact the ability to toler-
ate additional therapy postoperatively and therefore limit the 
ability to extrapolate gastric adenocarcinoma treatment data to 
patients with esophageal cancer. Our current study quantifies 
the impact of postoperative complications on outcomes and the 
use of adjuvant chemotherapy among patients with esophageal 
cancer. Although the NCDB does not have specific data avail-
able regarding postoperative morbidity, our definition based on 
TABLE 2.  Independent Predictors of Adjuvant Chemotherapy use After Esophagectomy
Predictor Odds Ratio Upper 95% CI Lower 95% CI p Value
Age (per decade) 0.58 0.49 0.70 <0.001
Female sex 0.74 0.41 1.33 0.308
Race (ref = white)
  Black 5.77 0.64 52.24 0.119
  Other 3.08 0.18 51.50 0.434
Charlson score 0.84 0.62 1.13 0.241
Education above median 1.12 0.72 1.73 0.615
Income above median 0.82 0.52 1.28 0.373
pT stage 0.93 0.76 1.13 0.453
Distance traveled (per 100 miles) 0.78 0.62 0.98 0.032
Complication related to surgery 0.45 0.30 0.67 <0.001
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unplanned readmission within 30 days or a length of stay of 
3 weeks or greater captures patients who did not have a com-
pletely uneventful postoperative course. Importantly, our study 
shows that patients who have postoperative complications but 
still receive AC have survival that is similar to that of those 
patients who have an uncomplicated course and are treated with 
AC as planned, and is markedly better than for patients who do 
not experience a complication but are also not treated with AC. 
This data can guide patient counseling, as patients reluctant to 
consider additional therapy may be more amenable if the poten-
tial benefits of improved survival are better quantified.
Recent evidence suggests that induction chemoradia-
tion followed by surgical resection is the optimal treatment 
for patients with locally advanced but resectable esophageal 
cancer.9–15 There are several potential reasons why patients 
in this current study may not have been given induction 
therapy. First, the patients may have been treated at insti-
tutions where induction therapy was not routinely consid-
ered. Second, induction therapy may have been considered 
inappropriate do to specific patient characteristics, such as 
medical comorbidities or previous chemotherapy or radia-
tion therapy. Third, the patients may have been understaged 
pretherapy due to limitations of current staging modali-
ties.33–38 Our study does suggest that adjuvant therapy likely 
provides benefit to patients who are primarily treated with 
surgery due to initial understaging. However, clinicians may 
FIGURE 2.  Kaplan–Meier survival curves for patients 
(A) treated with versus without adjuvant chemother-
apy; and (B) treated with versus without adjuvant 
chemotherapy and excluding patients experiencing a 
postoperative complication (defined as an unplanned 
readmission or length of stay >20 days).
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want to more strongly consider induction therapy before 
esophagectomy whenever there is suggestion of nodal or 
more advanced disease, considering our finding that only 
about half of patients get AC and therefore all of the recom-
mended treatment when nodal disease is discovered after 
primary therapy with esophagectomy.
Younger age and the absence of a complicated postop-
erative course were both strongly associated with the use of 
AC, although interestingly Charlson/Deyo comorbidity score 
did not seem to alter its use. However, it is likely that con-
siderable co-linearity between higher comorbidity scores and 
likelihood of postoperative complications, both of which were 
included in our statistical model, may explain the lack of sig-
nificance. Socioeconomic factors including race, income, and 
education level do not seem to have an independent effect on 
the use of AC, however longer distance to the treatment facil-
ity lowered the odds of receiving AC. Although this could be 
related to geographic and center-level variation, it more likely 
represents a logistical burden for patients who are required to 
travel longer distances to receive their care.
Although the primary purpose of this study was to exam-
ine adjuvant chemotherapy use, we also examined the addition 
of radiation therapy to AC. In an exploratory Cox proportional 
hazards model, the addition of radiation therapy to the model 
resulted in neither adjuvant radiation nor chemotherapy hav-
ing an independent association with long-term survival. As 
this was likely due to significant colinearity between the two 
variables (71% of the AC patients also received radiation 
therapy), we then conducted a comparison of survival among 
patients treated with only AC versus combined adjuvant 
chemoradiation, and found no significant difference between 
the two groups. These results suggest that the substantial sur-
vival advantage associated with adjuvant therapy is due to 
chemotherapy. Although radiation may confer some benefits 
in terms of local control as evidenced by the studies that inves-
tigated adjuvant therapy for gastric cancer, these benefits may 
be offset by complications related to treatment of the conduit 
after esophageal cancer resection. Our results suggest that 
among patients with node-positive disease after esophagec-
tomy, radiation does not affect overall survival. given these 
findings, more study is needed regarding the impact of post-
operative radiation therapy on patients recently treated with 
esophagectomy.
The NCDB offers significant advantages over exist-
ing studies due to its large size and population-based nature. 
Regardless, the database does have inherent limitations. First, 
this was a retrospective study, and as such is subject to intrinsic 
selection bias. Although our patient population was defined by 
fairly strict criteria regarding indications for AC (R0 resec-
tion and node-positive disease, in the absence of induction 
treatment), it is possible that some patients were not treated 
with AC due to comorbidities or the belief that they would not 
safely tolerate chemotherapy after the expected insult of an 
esophagectomy. Second, the NCDB does not provide specific 
complication data such as anastomotic leak, pneumonia, or 
sepsis, and therefore our definition of postoperative complica-
tions is based on measured indicators. Although we felt that 
an unplanned readmission or length of stay more than 20 days 
was clearly related to a nonroutine postoperative course, it is 
possible that the actual complication rate was much higher, 
and we were simply unable to detect less severe occurrences 
based on the criteria used. Lastly, cancer-specific survival and 
recurrence data are not available in the NCDB, both of which 
may be particularly important in our analyses of patients expe-
riencing postoperative complications.
In conclusion, adjuvant chemotherapy is associated 
with a substantial survival advantage for patients with positive 
nodal disease after esophagectomy. Esophagectomy remains a 
highly morbid procedure with considerable risk of postopera-
tive complications. Patients who can be rescued to proceed to 
AC despite complications fare and patients treated with AC 
but who had an uncomplicated course. In light of the meaning-
ful survival benefit associated with AC despite complications, 
great effort should be made to ensure that patients who expe-
rience a complicated course after esophagectomy are given 
strong consideration for treatment with AC if at all possible.
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TABLE 3.  Adjusted Predictors of Long-Term Mortality, After Cox Proportional Hazards Modeling
Risk factor/Predictor Hazard Ratio Upper 95% CI Lower 95% CI p Value
Adjuvant chemotherapy 0.67 0.50 0.90 0.008
Age (per decade) 1.11 0.97 1.27 0.13
Female sex 0.91 0.56 1.50 0.72
Race (ref = white)
  Black 2.15 0.78 5.94 0.138
  Other 8.07 1.08 60.12 0.042
Charlson score 1.16 0.93 1.45 0.198
Pathologic T stage (per unit) 1.57 1.31 1.87 <0.001
Facility volume (per 10 cases) 0.56 0.29 1.07 0.077
Complications related to surgery 1.51 1.10 2.08 0.012
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